Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Tops Biopharma Innovation Survey For First Time

New Entrants Include Seagen And Inctye

Executive Summary

Conducting sector survey for a tenth year, Idea Pharma’s Mike Rea said: “COVID-19 showed companies with more agile decision-making were more likely to succeed.”

You may also be interested in...



Pandemic Perspectives: COVID-19 Upended Drug Launches In Ways That Will Stick

Preliminary data from IQVIA suggest 2020 was one of the weakest in recent years for new launch trajectories although drug companies tell Scrip there are some lessons learned from promoting during the pandemic.

As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts

The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.

GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle

Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel